Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for AKRO

Stock Name	Akero Therapeutics Inc
Ticker	AKRO(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US00973Y1082
LEI	549300SI3KG74LBE2955

Show aggregate AKRO holdings

News associated with AKRO

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $81.57 Average Target Price from Analysts: Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in […] - 2025-09-05 02:52:56
Akero Therapeutics (NASDAQ:AKRO) Research Coverage Started at TD Cowen: TD Cowen assumed coverage on shares of Akero Therapeutics (NASDAQ:AKRO – Free Report) in a research note published on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $76.00 target price on the stock. AKRO has been the subject of several other research reports. Citigroup dropped their price target on shares of […] - 2025-08-07 02:54:52
Universal Beteiligungs und Servicegesellschaft mbH Invests $463,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO): Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,436 shares of the company’s stock, valued at approximately $463,000. A number of other […] - 2025-08-04 05:14:50
KLP Kapitalforvaltning AS Cuts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO): KLP Kapitalforvaltning AS decreased its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 12.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,600 shares of the company’s stock after selling 1,400 shares during the […] - 2025-07-31 05:14:49
Jennison Associates LLC Purchases Shares of 13,178 Akero Therapeutics, Inc. (NASDAQ:AKRO): Jennison Associates LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 13,178 shares of the company’s stock, valued at approximately $533,000. Several other institutional investors and hedge funds have also […] - 2025-07-23 06:20:51
Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Increased by Bank of New York Mellon Corp: Bank of New York Mellon Corp raised its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,665 shares of the company’s stock after acquiring an additional 12,235 shares […] - 2025-07-22 08:19:03
Bank of New York Mellon Corp Acquires 12,235 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO): Bank of New York Mellon Corp raised its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 212,665 shares of the company’s stock after buying an additional 12,235 shares during the quarter. Bank […] - 2025-07-22 07:24:51
Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells $1,534,800.00 in Stock: Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) CEO Andrew Cheng sold 30,000 shares of the company’s stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $51.16, for a total value of $1,534,800.00. Following the sale, the chief executive officer directly owned 520,757 shares of the company’s […] - 2025-07-14 06:16:53
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of “Buy” by Brokerages: Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last […] - 2025-07-14 05:38:47
Mirae Asset Global Investments Co. Ltd. Purchases 338 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO): Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 14.5% during the first quarter, HoldingsChannel reports. The firm owned 2,664 shares of the company’s stock after buying an additional 338 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Akero Therapeutics were worth […] - 2025-07-07 04:41:41
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Target Price from Analysts: Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have been assigned a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the […] - 2025-06-24 03:11:00
Millennium Management LLC Sells 57,892 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO): Millennium Management LLC decreased its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 77.6% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 16,736 shares of the company’s stock after selling 57,892 shares during the period. Millennium Management LLC’s holdings in Akero Therapeutics […] - 2025-06-10 05:18:54
Akero Therapeutics Sees Unusually High Options Volume (NASDAQ:AKRO): Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 3,105 call options on the company. This represents an increase of approximately 106% compared to the average volume of 1,508 call options. Insider Activity In other news, insider Timothy Rolph sold 12,500 shares of […] - 2025-06-10 02:00:51
Akero Therapeutics (NASDAQ:AKRO) Given New $64.00 Price Target at Bank of America: Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price raised by Bank of America from $63.00 to $64.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Other research analysts also recently issued research reports about the company. Citigroup reduced their price target on Akero Therapeutics […] - 2025-05-28 02:44:51
ProShare Advisors LLC Grows Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO): ProShare Advisors LLC boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 32.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 22,398 shares of the company’s stock after acquiring an additional 5,477 shares during the period. ProShare Advisors LLC’s holdings in Akero Therapeutics were worth $623,000 as of […] - 2025-05-26 05:16:50
Akero Therapeutics (NASDAQ:AKRO) Price Target Cut to $78.00 by Analysts at Citigroup: Akero Therapeutics (NASDAQ:AKRO – Free Report) had its price objective decreased by Citigroup from $80.00 to $78.00 in a research note issued to investors on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock. Several other analysts have also weighed in on AKRO. HC Wainwright raised their price objective on shares of Akero […] - 2025-05-14 04:58:49
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Average Price Target from Analysts: Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock […] - 2025-05-05 04:28:56
Sterling Capital Management LLC Boosts Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO): Sterling Capital Management LLC lifted its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 764.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,789 shares of the company’s stock after purchasing an additional 1,582 shares during the period. Sterling Capital Management LLC’s holdings in Akero […] - 2025-04-24 05:56:54
Vanguard Group Inc. Has $103.06 Million Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO): Vanguard Group Inc. raised its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 0.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,704,411 shares of the company’s stock after purchasing an additional 27,830 shares during the period. Vanguard Group Inc. owned approximately […] - 2025-04-10 04:38:50
KLP Kapitalforvaltning AS Invests $306,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO): KLP Kapitalforvaltning AS acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 11,000 shares of the company’s stock, valued at approximately $306,000. A number of other hedge funds and other institutional investors have also recently bought and sold shares of AKRO. Handelsbanken […] - 2025-04-07 05:06:49
Akero Therapeutics (NASDAQ:AKRO) and Rezolute (NASDAQ:RZLT) Head to Head Comparison: Rezolute (NASDAQ:RZLT – Get Free Report) and Akero Therapeutics (NASDAQ:AKRO – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings […] - 2025-03-26 04:10:42
Y Intercept Hong Kong Ltd Lowers Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO): Y Intercept Hong Kong Ltd lessened its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,950 shares of the company’s stock after selling 7,966 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Akero Therapeutics were worth $249,000 at […] - 2025-03-05 07:07:16
Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $75.00: Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price boosted by HC Wainwright from $72.00 to $75.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock. AKRO has been the topic of several other reports. Canaccord Genuity Group lifted their price target on shares of Akero […] - 2025-03-04 04:50:49
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Position Decreased by Global Retirement Partners LLC: Global Retirement Partners LLC lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 13.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,917 shares of the company’s stock after selling 740 shares during the period. Global […] - 2025-02-27 06:52:59
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $75.86 Consensus Target Price from Analysts: Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last […] - 2025-02-19 05:06:50
Technology Stocks Upended by China’s DeepSeek: The S&P 500 Index ($SPX ) (SPY ) Monday closed down -1.46%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.97%. March E-mini S&P futures (ESH25 ) are down by -1.38%, and March E-mini Nasdaq... - 2025-01-28 13:04:47
Stocks Hit by AI Jitters: The S&P 500 Index ($SPX ) (SPY ) today is down -1.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.68%. March E-mini S&P futures (ESH25 ) are down sharply by -1.70%, and March E-mini... - 2025-01-28 02:53:37

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc AKRO holdings

Date	Number of AKRO Shares Held	Base Market Value of AKRO Shares	Local Market Value of AKRO Shares	Change in AKRO Shares Held	Change in AKRO Base Value	Current Price per AKRO Share Held	Previous Price per AKRO Share Held
2025-09-26 (Friday)	6,415	USD 306,252	USD 306,252
2025-09-25 (Thursday)	6,415	USD 296,501	USD 296,501	0	USD -7,955	USD 46.22	USD 47.46
2025-09-24 (Wednesday)	6,415	USD 304,456	USD 304,456
2025-09-17 (Wednesday)	6,375	USD 268,898	USD 268,898	0	USD -2,677	USD 42.1801	USD 42.6
2025-09-16 (Tuesday)	6,375	USD 271,575	USD 271,575
2025-09-12 (Friday)	6,335	USD 275,319	USD 275,319
2025-09-11 (Thursday)	6,335	USD 284,632	USD 284,632

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of AKRO by Blackrock for IE00B3VWM098

Show aggregate share trades of AKRO

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -20 48.290* 43.72 Profit of 874 on sale
2025-07-31 BUY 60 48.850* 43.66
2025-06-30 SELL -40 53.360* 42.65 Profit of 1,706 on sale
2025-06-25 SELL -20 55.040* 42.38 Profit of 848 on sale
2025-06-20 SELL -40 54.200* 42.13 Profit of 1,685 on sale
2025-05-23 BUY 20 46.360* 40.52
2025-05-19 SELL -20 38.140* 40.34 Profit of 807 on sale
2025-05-15 SELL -60 39.960* 40.36 Profit of 2,421 on sale
2025-05-12 SELL -20 41.530* 40.37 Profit of 807 on sale
2025-05-09 SELL -20 39.850* 40.38 Profit of 808 on sale
2025-04-30 SELL -20 45.610* 40.13 Profit of 803 on sale
2025-04-24 SELL -40 40.990* 40.07 Profit of 1,603 on sale
2025-04-17 SELL -20 37.630* 40.16 Profit of 803 on sale
2025-04-15 SELL -60 38.080* 40.22 Profit of 2,413 on sale
2025-04-14 SELL -60 37.600* 40.24 Profit of 2,415 on sale
2025-04-09 SELL -80 37.360* 40.39 Profit of 3,231 on sale
2025-04-07 SELL -140 35.970* 40.51 Profit of 5,672 on sale
2025-04-04 SELL -200 36.730* 40.56 Profit of 8,112 on sale
2025-03-31 BUY 20 40.480* 40.56
2025-03-19 SELL -40 44.780* 40.16 Profit of 1,607 on sale
2025-03-14 SELL -120 44.150* 40.00 Profit of 4,800 on sale
2025-03-13 SELL -40 44.860* 39.93 Profit of 1,597 on sale
2025-03-12 SELL -680 45.850* 39.84 Profit of 27,094 on sale
2025-03-07 SELL -40 42.120* 39.72 Profit of 1,589 on sale
2025-03-06 SELL -60 43.670* 39.66 Profit of 2,380 on sale
2025-03-03 SELL -20 45.540* 39.41 Profit of 788 on sale
2025-02-28 SELL -120 49.120* 39.25 Profit of 4,710 on sale
2025-02-26 SELL -20 47.590* 38.97 Profit of 779 on sale
2025-02-25 SELL -60 47.470* 38.83 Profit of 2,330 on sale
2025-02-18 BUY 100 49.440* 37.51
2025-02-13 BUY 20 49.230* 36.75
2025-02-12 BUY 20 49.440* 36.49
2025-02-11 BUY 60 49.950* 36.21
2025-02-06 BUY 180 54.950* 35.06
2025-01-28 BUY 20 51.470* 31.45
2024-12-30 BUY 100 27.960* 31.37
2024-12-06 BUY 80 31.110* 31.41
2024-12-05 BUY 20 29.700* 31.47
2024-12-04 BUY 100 30.920* 31.49
2024-11-29 BUY 100 32.100* 31.47
2024-11-27 BUY 80 32.170* 31.41
2024-11-26 BUY 20 31.160* 31.42
2024-11-21 BUY 100 31.200* 31.34
2024-11-20 BUY 60 30.635* 31.38
2024-11-18 BUY 240 29.560* 31.52
2024-11-12 BUY 160 32.380* 31.46
2024-11-08 BUY 100 34.450* 31.25
2024-11-07 BUY 300 34.870* 30.97
2024-11-06 BUY 40 35.280* 30.61
2024-10-31 BUY 20 30.830* 29.92
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-20	48.290*	43.72 Profit of 874 on sale
2025-07-31	BUY	60	48.850*	43.66
2025-06-30	SELL	-40	53.360*	42.65 Profit of 1,706 on sale
2025-06-25	SELL	-20	55.040*	42.38 Profit of 848 on sale
2025-06-20	SELL	-40	54.200*	42.13 Profit of 1,685 on sale
2025-05-23	BUY	20	46.360*	40.52
2025-05-19	SELL	-20	38.140*	40.34 Profit of 807 on sale
2025-05-15	SELL	-60	39.960*	40.36 Profit of 2,421 on sale
2025-05-12	SELL	-20	41.530*	40.37 Profit of 807 on sale
2025-05-09	SELL	-20	39.850*	40.38 Profit of 808 on sale
2025-04-30	SELL	-20	45.610*	40.13 Profit of 803 on sale
2025-04-24	SELL	-40	40.990*	40.07 Profit of 1,603 on sale
2025-04-17	SELL	-20	37.630*	40.16 Profit of 803 on sale
2025-04-15	SELL	-60	38.080*	40.22 Profit of 2,413 on sale
2025-04-14	SELL	-60	37.600*	40.24 Profit of 2,415 on sale
2025-04-09	SELL	-80	37.360*	40.39 Profit of 3,231 on sale
2025-04-07	SELL	-140	35.970*	40.51 Profit of 5,672 on sale
2025-04-04	SELL	-200	36.730*	40.56 Profit of 8,112 on sale
2025-03-31	BUY	20	40.480*	40.56
2025-03-19	SELL	-40	44.780*	40.16 Profit of 1,607 on sale
2025-03-14	SELL	-120	44.150*	40.00 Profit of 4,800 on sale
2025-03-13	SELL	-40	44.860*	39.93 Profit of 1,597 on sale
2025-03-12	SELL	-680	45.850*	39.84 Profit of 27,094 on sale
2025-03-07	SELL	-40	42.120*	39.72 Profit of 1,589 on sale
2025-03-06	SELL	-60	43.670*	39.66 Profit of 2,380 on sale
2025-03-03	SELL	-20	45.540*	39.41 Profit of 788 on sale
2025-02-28	SELL	-120	49.120*	39.25 Profit of 4,710 on sale
2025-02-26	SELL	-20	47.590*	38.97 Profit of 779 on sale
2025-02-25	SELL	-60	47.470*	38.83 Profit of 2,330 on sale
2025-02-18	BUY	100	49.440*	37.51
2025-02-13	BUY	20	49.230*	36.75
2025-02-12	BUY	20	49.440*	36.49
2025-02-11	BUY	60	49.950*	36.21
2025-02-06	BUY	180	54.950*	35.06
2025-01-28	BUY	20	51.470*	31.45
2024-12-30	BUY	100	27.960*	31.37
2024-12-06	BUY	80	31.110*	31.41
2024-12-05	BUY	20	29.700*	31.47
2024-12-04	BUY	100	30.920*	31.49
2024-11-29	BUY	100	32.100*	31.47
2024-11-27	BUY	80	32.170*	31.41
2024-11-26	BUY	20	31.160*	31.42
2024-11-21	BUY	100	31.200*	31.34
2024-11-20	BUY	60	30.635*	31.38
2024-11-18	BUY	240	29.560*	31.52
2024-11-12	BUY	160	32.380*	31.46
2024-11-08	BUY	100	34.450*	31.25
2024-11-07	BUY	300	34.870*	30.97
2024-11-06	BUY	40	35.280*	30.61
2024-10-31	BUY	20	30.830*	29.92

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of AKRO

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	320,554	0	439,677	72.9%
2025-09-18	580,318	8,000	1,504,420	38.6%
2025-09-17	204,882	20	453,803	45.1%
2025-09-16	206,796	20	330,745	62.5%
2025-09-15	220,059	26	481,701	45.7%
2025-09-12	353,794	0	539,619	65.6%
2025-09-11	255,450	91	523,792	48.8%
2025-09-10	448,340	7,548	553,346	81.0%
2025-09-09	151,462	14,540	268,131	56.5%
2025-09-08	190,270	26,862	376,993	50.5%
2025-09-05	117,683	0	243,944	48.2%
2025-09-04	194,348	29	609,138	31.9%
2025-09-03	127,854	3	245,662	52.0%
2025-09-02	116,986	3,904	277,827	42.1%
2025-08-29	85,173	0	146,209	58.3%
2025-08-28	122,035	238	187,638	65.0%
2025-08-27	153,819	113	232,967	66.0%
2025-08-26	92,304	4,102	207,519	44.5%
2025-08-25	96,706	0	144,623	66.9%
2025-08-22	146,180	0	328,681	44.5%
2025-08-21	99,543	200	166,233	59.9%
2025-08-20	186,444	0	265,086	70.3%
2025-08-19	135,620	0	193,668	70.0%
2025-08-18	108,395	0	171,507	63.2%
2025-08-15	554,663	5	878,289	63.2%
2025-08-14	325,703	13,249	531,753	61.3%
2025-08-13	127,086	0	277,108	45.9%
2025-08-12	187,432	30,605	288,844	64.9%
2025-08-11	293,883	13,502	490,123	60.0%
2025-08-08	199,064	0	355,719	56.0%
2025-08-07	275,529	0	721,339	38.2%
2025-08-06	963,438	211	1,390,492	69.3%
2025-08-05	318,638	4,289	433,703	73.5%
2025-08-04	238,397	92	375,442	63.5%
2025-08-01	223,655	714	301,118	74.3%
2025-07-31	224,466	97	335,691	66.9%
2025-07-30	131,329	0	227,512	57.7%
2025-07-29	99,368	49	195,575	50.8%
2025-07-28	169,588	7	309,206	54.8%
2025-07-25	92,231	60	188,784	48.9%
2025-07-24	79,791	65	200,044	39.9%
2025-07-23	133,901	77	303,687	44.1%
2025-07-22	82,616	50	289,833	28.5%
2025-07-21	89,737	216	210,901	42.5%
2025-07-18	95,387	211	239,968	39.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE